Viral Vector CDMO Market to Reach USD 5.8 Billion by 2034

The global viral vector CDMO market is experiencing rapid growth, driven by the increasing demand for gene and cell therapies. The market size was USD 1.1 billion in 2025 and is projected to reach USD 5.8 billion by 2034, growing at a compound annual rate of ~19%.

The North American region holds the largest share of the global viral vector CDMO market, accounting for approximately 35% in 2025. This growth is attributed to the expanding pipeline of gene and cell therapies, increasing reliance on outsourcing by biotechnology and pharmaceutical companies, growing investments in biotechnology research and development, and the rising adoption of viral vectors for vaccine production and infectious disease applications.

The European market is also experiencing steady expansion, driven by the region's thriving gene and cell therapy landscape, rising investments from both public and private sectors, and the presence of established CDMOs equipped with advanced manufacturing technologies. Key companies in the market include Lonza Group, Thermo Fisher Scientific, Catalent, Oxford Biomedica, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, WuXi AppTec, Merck KGaA, AGC Biologics, Takara Bio, Samsung Biologics, Curia Global, GenScript ProBio, Creative Biogene, VectorBuilder, Aldevron, FinVector, Yposkesi, VGXI, and Genezen.